Previous 10 | Next 10 |
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada Canada NewsWire New generic Multiple Sclerosis treatment option, Pr Glatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the larg...
2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...
2024-04-10 11:58:51 ET More on Estee Lauder, Hasbro, etc. Paramount Global's Sale Will Not Be Easy, Cheap, Or Fast Paramount: What The Skydance Proposal Means For Investors Paramount: Apollo Coming Around The Turn Ready To Pounce If Skydance Deal Falters ...
2024-04-09 05:49:33 ET Summary After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and comparisons year over year will start to be favorable in th...
2024-04-08 17:01:16 ET Summary Viatris Inc. is a deep value pharmaceutical company with a low valuation and a 4.1% yield. Viatris has seen a slowdown in top line decline and has a promising pipeline of potential blockbuster drugs. Management is de-risking the balance sheet and...
2024-04-04 08:55:15 ET More on Viatris Viatris Stock Is Still Worth Buying Viatris Inc. (VTRS) R&D Event (Transcript) Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued Teva and Viatris revive chance to dispute J&J's schizophrenia dr...
2024-04-01 12:17:16 ET NYSE: TEVA NASDAQ: VTRS NYSE: JNJ More on Johnson & Johnson, Teva Pharmaceutical, etc. Viatris Stock Is Still Worth Buying With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Viatris Inc. (VTRS) R&...
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. comme...
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States PR Newswire PITTSBURGH , April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of ...
2024-03-30 01:59:08 ET Summary Viatris Inc. stock has risen by 26.7% since my November 2023 bullish call, outperforming the S&P 500 Index. It's time to update my thesis - read on. Although net sales declined (as did EBITDA and net profit) in 2023, we saw an improvement in the ...
News, Short Squeeze, Breakout and More Instantly...
Viatris Inc. Company Name:
VTRS Stock Symbol:
NASDAQ Market:
Thursday, Viatris Inc (NASDAQ:VTRS) reported first-quarter EPS of $0.67, which is in line with the consensus. The company reported s...
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges PR Newswire PITTSBURGH , May 9, 2024 /PRNewswire/ -- Reports Total Revenues of $3.66 Billion ; U.S. GAAP Net Earnings of $113.9 Million ; Adju...
Viatris to Participate in the BofA Securities 2024 Health Care Conference PR Newswire PITTSBURGH , May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 H...